Clinical Trials
3 trialsNCT01565200 2025-03-31
ZEPHIR
Jules Bordet Institute
Phase 2 Completed
NCT04757090 2021-12-23
89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
Washington University School of Medicine
Phase 2 Withdrawn
NCT01832051 2015-11-05
Clinical Value of 89Zr-trastuzumab PET
University Medical Center Groningen
Phase 2 Completed